In this episode of Vital Psychedelic Conversations, Kyle Buller interviews Dr. Devon Christie: Senior Lead of Psychedelic Programs with Numinus Wellness, clinical instructor, counselor, and Co-Investigator and study therapist for a Canadian MAPS-sponsored trial investigating MDMA-assisted therapy for PTSD. She talks about the importance of biomedical ethics and the unique considerations of psychedelic-assisted therapy: how psychedelics enhance the vulnerability and suggestibility in a well-established power dynamic, and how being aware of your power and biases is of the utmost importance towards not influencing your patient’s experience. And she talks about the complications of touch and establishing (and honoring) informed consent; how true mindfulness can cultivate a greater capacity for self-regulation; how to handle situations where the client wants to know if a memory is real or not; the idea of psychedelics as placebos; and other therapeutic concepts like harm of neglect, undue influence, making pleasure a virtue, cultivating agency, combating physician burnout, and the expectation effect.

The post PT306 – Dr. Devon Christie – Vital Psychedelic Conversations appeared first on Psychedelics Today.

Previous articleMydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update
Next articleCanada’s SAP Expansion Signals a Step Forward for Psychedelics